A simple and rapid HPLC method for quantitation of interferon-α2b in dosage forms and delivery systems

Zarrin, Abdolhossein; Foroozesh, Mahshid; Hamidi, Mehrdad; Mohammadi-Samani, Soliman

doi:10.1016/j.jchromb.2006.01.029

Cited by 8 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specific HPLC conditions were reported by the same group for the analysis of recombinant and native human luteinizing hormone and human chorionic gonadotropin preparations [56]. A rapid and easy-to-use method was developed for the quantitative analysis of interferon-beta2b in pharmaceuticals [57]. Another method was developed and applied for the determination of recombinant human interferon omega in the fermentation broth of the yeast Pichia pastoris [58].…”

Section: Applications Of Conventional Rplc In Protein Analysismentioning

confidence: 99%

New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: Theory and applications

Fekete

Veuthey

Guillarme

2012

Journal of Pharmaceutical and Biomedical Analysis

131

View full text Add to dashboard Cite

Section: Applications Of Conventional Rplc In Protein Analysismentioning

confidence: 99%

New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: Theory and applications

Fekete

Veuthey

Guillarme

2012

Journal of Pharmaceutical and Biomedical Analysis

131

View full text Add to dashboard Cite

“…High-Performance Liquid Chromatography (HPLC) was used with the help of an Ultimate3000 device (Thermo Fisher Scientific, Munich, Germany). A portion (5.4 mg) of the commercially available Drug Reaferon EC 5 × 10 6 IU lyophilizate was dissolved in 540 µL of the mobile phase (10% B), centrifuged at 15,000 rpm for 5 min, and analyzed as previously described in [44] under the conditions listed below. Stationary phase: Pinnacle II C18 150 × 4.6 mm, 5 µm, 140 A, column oven temperature 30 • C. Mobile phase (A)-0.1% trifluoroacetic acid in water (Type I); mobile phase (B)-0.1% trifluoroacetic acid in acetonitrile (HPLC grade, Panreac).…”

Section: Concentration Of Ifnα In Commercially Available Drug Reafero...mentioning

confidence: 99%

UMAOH Calcium Phosphate Coatings Designed for Drug Delivery: Vancomycin, 5-Fluorouracil, Interferon α-2b Case

et al. 2022

View full text Add to dashboard Cite

Drug delivery systems based on calcium phosphate (CaP) coatings have been recently recognized as beneficial drug delivery systems in complex cases of bone diseases for admission of drugs in the localized area, simultaneously inducing osteoinduction because of the bioavailable Ca and P ions. However, micro-arc oxidation (MAO) deposition of CaP does not allow for the formation of a coating with sufficient interconnected porosity for drug delivery purposes. Here, we report on the method to deposit CaP-based coatings using a new hybrid ultrasound-assisted MAO (UMAOH) method for deposition of coatings for drug delivery that could carry various types of drugs, such as cytostatic, antibacterial, or immunomodulatory compositions. Application of UMAOH resulted in coatings with an Ra roughness equal to 3.5 µm, a thickness of 50–55 µm, and a combination of high values of internal and surface porosity, 39 and 28%, respectively. The coating is represented by the monetite phase that is distributed in the matrix of amorphous CaP. Optimal conditions of coating deposition have been determined and used for drug delivery by impregnation with Vancomycin, 5-Fluorouracil, and Interferon-α-2b. Cytotoxicity and antimicrobial activity of the manufactured drug-carrying coatings have been studied using the three different cell lines and methicillin-resistant S. aureus.

show abstract

“…Considering the analytical methods, the IFN-α quantification in human serum or plasma is often undetectable by ELISA since the cytokine is in the order of picogram/milliliter [13]. Zarrin et al [14] reported a simple and rapid HPLC method with LOD and LOQ of 0.125 and 0.25 MIU/ml, equivalent to 0.2 and 0.4 μg/ml, respectively [15]. However, chromatographic methods have some drawbacks as the need of special columns and equipment, the use of organic solvents, the high expertise for using and interpreting the results and the lack of long-term reproducibility.…”

mentioning

confidence: 99%

Design and Validation of an Immuno-PCR Assay for IFN-Α2B Quantification in Human Plasma

et al. 2019

View full text Add to dashboard Cite

Aim: Nowadays, IFN-α is considered a promising therapeutic target for systemic lupus erythematosus. An immuno-PCR (iPCR) was developed to quantify low amounts of IFN-α in human plasma followed by a deep analysis of the methodologic robustness throughout quality by design approach. Results: An accurate, sensitive, selective and versatile iPCR was validated. The critical iPCR procedural steps were identified, applying a Plackett–Burman design. Also, this assay demonstrated an outstanding LOD of 0.3 pg/ml. A significant aspect relies on its high versatility to detect and quantify other cytokines in human plasma as the appropriate biotinylated antibody is employed. Conclusion: This reliable iPCR assay can be clinically used as an alternative method for quantitating and detecting low IFN-α2b concentrations in human plasma samples.

show abstract

A simple and rapid HPLC method for quantitation of interferon-α2b in dosage forms and delivery systems

Cited by 8 publications

References 17 publications

New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: Theory and applications

New trends in reversed-phase liquid chromatographic separations of therapeutic peptides and proteins: Theory and applications

UMAOH Calcium Phosphate Coatings Designed for Drug Delivery: Vancomycin, 5-Fluorouracil, Interferon α-2b Case

Design and Validation of an Immuno-PCR Assay for IFN-Α2B Quantification in Human Plasma

Contact Info

Product

Resources

About